论文部分内容阅读
Objective: Banxia Baizhu Tianma Decoction (半夏白术天麻汤, BBTD) combined with Xuefu Zhuyu Decoction (血府逐瘀汤, XFZYD) is widely used to treat essential hypertension in China, but its efficacy remains largely unexplored. We systemically summarized relevant evidence from randomized controlled trials (RCTs) to assess the therapeutic efficacy of BBTD+XFZYD. Methods: This review retrieved 6 databases like Pubmed, Cochrane Library, Embase, CNKI, et al. RCTs of BBTD+XFZYD plus conventional Western drugs (experimental group) and conventional Western drugs alone (control group) for hypertension was collected from the database establishment to August 5, 2020. And the outcomes included clinical total effective rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), nitric oxide (NO) and endothelin-1 (ET-1). All studies' risk of bias were assessed by the Cochrane Collaboration tool 5.1.0. The data was statistically analyzed by RevMan5.3 Software. Results: Six studies with 608 participants were identified. About duration of treatment, 4 studies were 1 month, 2 studies were 2 months. The quality presented a high risk of bias. The experimental group showed that clinical total effective rate of the 1-month and 2-month was higher (P<0.00001), the systolic pressure was significantly lower (P<0.05), the NO increased (P<0.00001), and the ET-1 decreased (P<0.00001) compared with the conventional Western drugs used alone. However, DBP was significantly lower (P<0.05) at 2 months of treatment. Conclusion: BBTD+XFZYD plus conventional Western drugs might reduce blood pressure, improve clinical efficacy, repair endothelial function, but still need high-quality RCTs to better assess the outcomes.